| Literature DB >> 33737242 |
Guillaume Daziano1, Nicolas Blondeau1, Sophie Béraud-Dufour1, Amar Abderrahmani2, Carole Rovère1, Catherine Heurteaux1, Jean Mazella1, Patricia Lebrun3, Thierry Coppola4.
Abstract
Deterioration of insulin secretion and pancreatic beta-cell mass by inflammatory attacks is one of the main pathophysiological features of type 2 diabetes (T2D). Therefore, preserving beta-cell mass and stimulating insulin secretion only in response to glucose for avoiding the hypoglycemia risks, are the most state-of-the-art option for the treatment of T2D. In this study we tested two correlated hypothesis that 1/ the endogenous peptide released from sortilin, known as PE, that stimulates insulin secretion only in response to glucose, protects beta-cells against death induced by cytokines, and 2/ Spadin and Mini-Spadin, two synthetic peptides derived from PE, that mimic the effects of PE in insulin secretion, also provide beneficial effect on beta-cells survival. We show that PE and its derivatives by inducing a rise of intracellular calcium concentration by depolarizing the membrane protect beta-cells against death induced by Interleukin-1β. Using biochemical, confocal imaging and cell biology techniques, we reveal that the protective effects of PE and its derivatives rely on the activation of the CaM-Kinase pathway, and on the phosphorylation and activation of the transcription factor CREB. In addition, Mini-Spadin promotes beta-cell proliferation, suggesting its possible regenerative effect. This study highlights new possible roles of PE in pancreatic beta-cell survival and its derivatives as pharmacological tools against diabetes.Entities:
Keywords: Beta-cell protection; CREB activation; Calcium influx; Neuropeptide; Sortilin-released propeptide
Mesh:
Substances:
Year: 2021 PMID: 33737242 DOI: 10.1016/j.phrs.2021.105539
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658